/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.
BERGEN, Norway, May 28, 2024 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical
'Most people think carcinomatosis is a death sentence, but there are different treatment modalities that I offer to patients. And that's something that is pretty unique to UT Health San Antonio,' said Dr. Mio Kitano, a surgical oncologist.